Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study
Open Access
- 16 September 2022
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (1) , 46-55
Abstract
Aims: To describe glucose‐lowering treatment regimens and glycated haemoglobin (HbA1c) trajectories in individuals with type 2 diabetes (T2D) over 36 months of follow‐up from the start of second‐line therapy. Materials and Methods: This data analysis from the 3‐year, observational DISCOVER study programme included 14 687 participants from 37 countries with T2D initiating second‐line glucose‐lowering therapy. Treatment and HbA1c data were collected at baseline (start of second‐line therapy) and at 6, 12, 24 and 36 months. Treatment regimen changes over follow‐up were analysed using the McNemar test, with carry‐forward imputation for intermediate missing values. Results: A total of 11 592 participants had treatment data at baseline and 36 months, and 11 882 had HbA1c data at baseline. At baseline and 36 months, respectively, rates of oral monotherapy use were 12.1% and 12.4% ( P = 0.22), rates of dual oral therapy use were 63.4% and 47.6% ( P < 0.0001), rates of ≥ triple oral therapy use were 17.5% and 25.4% ( P < 0.0001), and rates of injectable treatment use were 7.0% and 13.7% ( P < 0.0001). Use of injectable drugs was most common among participants with an HbA1c level ≥64 mmol/mol (≥8.0%). Overall, 42.9% of participants changed treatment during follow‐up. Mean HbA1c levels at baseline and 6 months were 67 mmol/mol (8.3%) and 55 mmol/mol (7.2%), respectively, remaining stable thereafter. Conclusions: Dual oral therapy was the most common treatment regimen at the start of second‐line treatment, and over half of the participants remained on the same treatment during follow‐up.Keywords
Funding Information
- AstraZeneca (N/A)
This publication has 20 references indexed in Scilit:
- Clinical inertia versus overtreatment in glycaemic managementThe Lancet Diabetes & Endocrinology, 2018
- Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A ProtocolDiabetes Therapy, 2017
- Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study programJournal of Diabetes and its Complications, 2017
- Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in E urope and the USADiabetes, Obesity and Metabolism, 2017
- Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health SystemDiabetes Care, 2016
- Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK databaseCurrent Medical Research and Opinion, 2016
- McNemar Test2014
- Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines ListsPLOS ONE, 2014
- Clinical Inertia in People With Type 2 DiabetesDiabetes Care, 2013
- Multifaceted Determinants for Achieving Glycemic ControlDiabetes Care, 2009